Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Depression affect sits at the center of this dementia and brain health question.
Yes, depression can significantly affect MMSE test results, often causing scores that appear lower than a person’s actual cognitive ability. This happens because depression interferes with the mental processes the test measures—particularly concentration, processing speed, and motivation to perform well. When a 68-year-old woman came to her doctor complaining of memory problems, her MMSE score was 22, suggesting mild cognitive impairment.
However, after her depression was treated with an SSRI over eight weeks, her MMSE score improved to 27, revealing that her cognitive decline had been masked by depression rather than caused by actual neurological damage. The relationship between depression and MMSE performance is so well-documented that it’s become a clinical concern in geriatric medicine. Depression can create what clinicians call “pseudodementia”—cognitive symptoms that mimic dementia but are actually reversible with proper treatment. This distinction matters enormously because a misdiagnosis based on a depression-affected MMSE score might lead to unnecessary neurological workups, incorrect diagnoses of Alzheimer’s disease or other dementias, and missed opportunities to treat the underlying depression.
Table of Contents
- How Does Depression Interfere With MMSE Testing?
- Distinguishing Depression Effects From True Cognitive Decline
- Depression’s Specific Impact on MMSE Subcategories
- The Clinical Decision Point—When to Retest After Depression Treatment
- Comorbidity—When Depression and Actual Dementia Coexist
- Medication Factors and MMSE Performance
- The Future of Depression Screening in Dementia Evaluation
- Conclusion
- Frequently Asked Questions
How Does Depression Interfere With MMSE Testing?
Depression affects MMSE performance through multiple neurological and behavioral pathways. The test requires sustained attention, quick processing, and motivation—all functions depression specifically impairs. When someone is depressed, their prefrontal cortex (the brain region responsible for attention and executive function) shows reduced activity. This makes it harder to focus on the test questions, recall information on demand, or complete tasks that require cognitive effort. A person might know the answer to a question about what day it is but struggle to retrieve that information because depression has slowed their mental processing.
The motivational component is equally important. Depression creates apathy—a profound lack of interest or drive to engage with activities, including cognitive testing. Someone taking the MMSE while depressed might not try as hard on word recall questions or might rush through attention tasks. Research shows that depression-related apathy can lower MMSE scores by 2-5 points on average, enough to move someone from normal range into mild impairment territory. In contrast, someone with early Alzheimer’s disease who isn’t depressed might perform better on the same test despite having more actual neurological damage, because they’re engaged and motivated to do well.
Distinguishing Depression Effects From True Cognitive Decline
The clinical challenge is determining whether low MMSE scores reflect actual dementia or depression’s cognitive effects. Several warning signs suggest depression rather than neurological disease. Depression typically causes sudden onset of cognitive complaints (“I woke up one day and couldn’t remember things”), while dementia usually progresses gradually over months and years. Additionally, people with depression-related cognitive impairment often have sharp insight into their memory problems and worry extensively about them, whereas those with actual dementia frequently lack awareness of their deficits.
A crucial limitation of the MMSE is that it doesn’t distinguish between these conditions. The test itself provides no information about the cause of poor performance. Clinicians must look beyond the score, considering the person’s mood history, onset of symptoms, presence of depressive symptoms like sleep disturbance and hopelessness, and response to treatment. Someone with depression will typically show improvement in MMSE scores once depression treatment begins, while someone with Alzheimer’s disease will continue to decline regardless of antidepressant therapy. However, this can take weeks to months, and in the meantime, the patient may receive unnecessary testing or experience the emotional burden of believing they have dementia.
Depression’s Specific Impact on MMSE Subcategories
The MMSE measures five main cognitive domains: orientation, registration, attention, recall, and language. Depression doesn’t affect these equally. Orientation questions—like “What year is it?”—typically remain intact because this information is automatic and well-rehearsed. Attention and processing speed questions show the most depression-related decline.
The serial 7s task (counting backward by sevens) becomes particularly difficult because it requires sustained attention and working memory, both severely compromised by depression. A 72-year-old man with depression scored well on orientation (10/10) and language (8/9) but scored only 1/5 on the serial 7s task and had difficulty recalling three words after a delay, giving him a total MMSE of 24. Once his depression was treated, that same man completed the serial 7s task accurately and recalled all three words, raising his score to 29. This pattern—preserved orientation and language but impaired attention and recall—is a classic presentation of depression-related cognitive impairment rather than dementia. In true Alzheimer’s disease, the pattern is often reversed, with orientation and language being more severely affected in later stages.
The Clinical Decision Point—When to Retest After Depression Treatment
Clinicians increasingly recommend retesting with the MMSE after depression has been treated, rather than making permanent cognitive decline diagnoses based on a single low score obtained during depression. However, this creates a practical tradeoff. Waiting weeks or months for antidepressants to take effect delays diagnosis if someone does have actual dementia. Additionally, not everyone responds equally to depression treatment, and some people have both depression and dementia simultaneously, making the clinical picture even more complex.
The best practice involves balancing urgency with caution. If someone presents with low MMSE scores and depression symptoms, clinicians typically start depression treatment while monitoring for cognitive improvement. If significant improvement occurs (typically a 3-point or greater improvement), depression was likely the culprit. If scores remain low or continue declining despite depression treatment, further neurological workup is warranted. This approach works better than treating MMSE scores as permanent markers of cognitive status, but it does require patience and multiple testing sessions, which some people find frustrating.
Comorbidity—When Depression and Actual Dementia Coexist
A major complication is that depression and dementia aren’t mutually exclusive. Approximately 30-40% of people with dementia also experience depression, and depression itself increases dementia risk in older adults. When both conditions are present, MMSE scores become even harder to interpret. Someone might have both depression-related cognitive slowing and actual memory loss from Alzheimer’s pathology.
In these cases, MMSE scores will be lower than either condition alone would produce, and treating depression might improve scores somewhat but won’t restore them to normal if dementia is present. This comorbidity carries a serious warning: clinicians must not assume that depression treatment alone will restore cognition to baseline if dementia is also present. Some people undergo depression treatment expecting their memory to fully return, only to discover they still have significant cognitive deficits. Conversely, clinicians should not prematurely diagnose dementia in someone presenting with both depression and cognitive complaints without first treating the depression and reassessing. The only reliable way to separate these contributions is through longitudinal follow-up and sometimes advanced neuroimaging, neither of which the MMSE itself provides.
Medication Factors and MMSE Performance
Certain antidepressants and other medications used in depression treatment can themselves affect cognitive performance, creating another layer of complexity. Tricyclic antidepressants, while less commonly prescribed now, are known for causing cognitive side effects and sedation that might further lower MMSE scores in the short term. SSRIs generally have fewer cognitive effects, but some people experience brain fog or difficulty concentrating early in treatment.
This means that immediately after starting depression medication, MMSE scores might temporarily dip further before improving. A patient might score lower on MMSE two weeks into antidepressant therapy than when initially tested, then show improvement by week six as both the depression and medication side effects improve. Additionally, many older adults with depression take multiple medications—pain relievers, blood pressure drugs, sleep aids—some of which independently affect cognition. The medication-depression-cognition interaction is complex, and MMSE interpretation requires understanding not just mood symptoms but the entire medication landscape.
The Future of Depression Screening in Dementia Evaluation
Modern dementia evaluation increasingly incorporates depression screening as a standard component, recognizing that MMSE scores alone are insufficient for diagnosis. Some clinicians now use validated depression screening tools like the PHQ-9 (Patient Health Questionnaire-9) or GDS (Geriatric Depression Scale) alongside cognitive testing to better interpret results. Newer biomarker tests—blood tests for tau and amyloid proteins—may eventually help clarify whether someone has dementia pathology independent of current MMSE performance, though these tests are still being refined for routine clinical use.
The key insight emerging from recent research is that depression screening and treatment should be routine parts of dementia workup, not afterthoughts. By identifying and treating depression early, many people can avoid incorrect dementia diagnoses and recover their actual cognitive function. This represents a shift from treating MMSE as a definitive diagnostic tool to treating it as one piece of information that must be interpreted in context of mood, medication, and other clinical factors.
Conclusion
Depression can substantially lower MMSE scores through effects on attention, processing speed, and motivation, sometimes creating the appearance of dementia when actual cognitive decline is minimal or absent. The key to avoiding misdiagnosis is recognizing that low MMSE scores during depression don’t prove permanent cognitive damage, and that retesting after depression treatment is often warranted. If scores improve significantly after depression treatment, depression was likely responsible; if they don’t improve, further neurological evaluation is necessary.
Understanding the depression-MMSE relationship matters because it affects real decisions about diagnosis, treatment, and quality of life. A person misdiagnosed with dementia may experience unnecessary anxiety and become unnecessarily disabled, while someone whose depression goes untreated as clinicians focus on pursuing a dementia diagnosis misses the chance for effective treatment. The best clinical approach combines MMSE testing with depression screening, serial testing to track changes, and willingness to revise initial impressions as the clinical picture becomes clearer.
Frequently Asked Questions
Can depression completely fake dementia on the MMSE test?
Depression can produce scores in the dementia range, but usually not perfectly mimicking dementia patterns. Orientation and language tend to be preserved in depression-related cognitive impairment, while they’re more often affected in actual dementia. However, careful testing and clinical follow-up are needed to distinguish them.
How long does it take for MMSE scores to improve after depression treatment?
Improvement typically becomes noticeable within 4-8 weeks as antidepressants take effect and mood lifts. However, this varies significantly by individual and by the specific antidepressant used. Full improvement might take 12 weeks or longer.
Should someone with depression avoid MMSE testing?
No, MMSE testing can be valuable, but results should be interpreted cautiously during depression and may warrant retesting after treatment. The test provides useful information, but depression context is essential for accurate interpretation.
What should I do if I scored low on MMSE during depression?
Discuss your scores with your doctor in the context of your depression symptoms and timeline. Work on treating your depression, and plan for retesting after treatment has had time to take effect. Don’t assume low scores mean permanent cognitive decline.
Can depression cause permanent cognitive damage visible on MMSE?
While chronic depression may have some long-term effects on brain function, the acute cognitive impairment depression causes on MMSE testing is generally reversible with treatment. Permanent damage is more associated with actual dementia diseases, not depression alone.
Is MMSE still reliable if someone is taking antidepressants?
MMSE is still useful, but the results require careful interpretation. Some antidepressants have minimal cognitive effects, while others might temporarily worsen scores early in treatment. Timing of testing relative to medication changes matters.
You Might Also Like
- Can a UTI Lower an MMSE Score Temporarily?
- Can Delirium Cause a Low MMSE Score?
- What Is a Normal MMSE Score for Older Adults?
For more, see Alzheimer’s Association — clinical trials.
